Stocks · Health care · Pharmaceutical Preparations

Roivant Sciences Ltd.

ROIV Clue Score19
Bermuda Fiscal year ends March CIK 0001635088 Results filed 6 Aug 2026

What the insiders did Net selling

By person

15 insiders · 118 transactions
828×

Matthew Gline holds 828 times base salary in stock. $600.90M of shares against $725.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew Gline last reported holding, valued at $36.31, the price Common Shares was last bought or sold at on the open market here, on 3 Nov 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Keith S Manchester
Director
—
$154.47M (20)
−$154.47M
15,442,623
2.14%
$560.72M
−60.1%
Daniel Allen Gold
Director
—
$147.38M (19)
−$147.38M
22,654,981
3.14%
$822.60M
−65.2%
QVT Financial LP entity
Director by Deputization
—
$147.38M (19)
−$147.38M
13,689,166
1.90%
$497.05M
−75.6%
Mayukh Sukhatme
President & CIO
—
$109.13M (13) scheduled
−$109.13M
18,563,884
2.57%
$674.05M
−17.5%
Vivek Ramaswamy
10% owner
—
$105.88M (6) scheduled
−$105.88M
47,011,612
6.51%
$1.71B
−12.0%
Eric Venker
President & Immunovant CEO
—
$91.40M (19) scheduled
−$91.40M
999,154
0.1383%
$36.28M
+61.8%
Frank Torti
President and Vant Chair
—
$82.04M (3) scheduled
−$82.04M
13,495,893
1.87%
$490.04M
—
Matthew Gline
CEO
—
$46.17M (4) scheduled
−$46.17M
16,549,136
2.29%
$600.90M
−4.7%
Richard Pulik
CFO
—
$9.12M (2) scheduled
−$9.12M
269,681
0.0373%
$9.79M
−4.4%
Meghan Fitzgerald
Director
—
$3.27M (5) scheduled
−$3.27M
41,162
0.0057%
$1.49M
+40.1%
Melissa B, Epperly
Director
—
$2.65M (7) scheduled
−$2.65M
15,351
0.0021%
$557.39K
−59.6%
Jennifer Humes
Chief Accounting Officer
—
$384.07K (1)
−$384.07K
106,419
0.0147%
$3.86M
+20,484%
Rakhi Kumar
Chief Accounting Officer
—
—
—
162,306
0.0225%
$5.89M
−22.1%
Ilan Oren
Director
—
—
—
124,490
0.0172%
$4.52M
+27.2%
James C Momtazee
Director
—
—
—
112,265
0.0155%
$4.08M
+19.9%